RNA interference: New therapeutics in allergic diseases

Current Gene Therapy

Volumn 8, Issue 4, 2008, Pages 236-246

  Lee, Chen Chen ^a   Chiang, Bor Luen ^b,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Allergy; Cytokine; Gene therapy; RNAi; shRNA; siRNA; Susceptibility genes; Transcription factor

Indexed keywords

ADENOVIRUS VECTOR; DOUBLE STRANDED RNA; EOTAXIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5; LENTIVIRUS VECTOR; MICRORNA; PARVOVIRUS VECTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT6 PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR GATA 3; VERY LATE ACTIVATION ANTIGEN 4; VIRUS VECTOR;

ALLERGIC DISEASE; ASTHMA; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; DRUG POTENCY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOSOMAL GENE DELIVERY SYSTEM; LOW DRUG DOSE; NONHUMAN; NONVIRAL GENE THERAPY; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TH2 CELL; TRANSCRIPTION INITIATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; HUMANS; HYPERSENSITIVITY; MICRORNAS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

ANIMALIA;

EID: 54749147546     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652308785160692     Document Type: Review

References (136)

1. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into Petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990; 2: 279-89.
2. Cogoni C, Macino G. Post-transcriptional gene silencing across kingdoms. Curr Opin Genet Dev 2000; 10: 638-43.
3. Cogoni C, Irelan JT, Schumacher M, Schmidhauser TJ, Selker EU, Macino G. Transgene silencing of the al-1 gene in vegetative cells of Neurospora is mediated by a cytoplasmic effector and does not depend on DNA-DNA interactions or DNA methylation. EMBO J 1996; 15: 3153-63.
4. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
5. Zamore PD, Tuschl T, Sharp PA, Bartel DP. Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101: 25-33.
6. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 2005; 123: 607-20.
7. Parker JS, Roe SM, Bradford D. Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature 2005; 434: 663-6.
8. Ma JB, Ye K, Patel DJ. Structural oasis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature 2004; 434: 663-6.
9. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev 2001; 15: 188-200.
10. Orban TI, Izaurralde E. Decay of mRMAs targeted by RISC requires XRN1, the Ski complex and the exosome. RNA 2005; 11: 459-69.
11. Hutvagner G, Zamore PD. A micro-RNA in a multiple-turnover RNAi enzyme complex. Science 2002; 297: 2056-60.
12. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 5: 522-31.
13. Bartel DP, Chen CZ. Micro-managers of gene expression: the potentially widespread influence of metazoan micro-RNAs. Nat Rev Genet 2004; 5: 396-400.
14. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene in lin-4 encodes small RNAs with anti-sense complementarity to lin-14. Cell 1993; 75: 843-54.
15. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R. Micro-RNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 2005; 7: 719-23.
16. Yekta S, Shih IH, Bartel DP. Micro-RNA-directed cleavage of Hoxb8 mRNA. Science 2004; 304: 594-6.
17. Lee Y, Kim M, Han J, et al. Micro-RNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23: 4051-60.
18. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human micro-RNAs. Nat Struct Mol Biol 2006, 13: 1097-101.
19. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates micro-RNA processing. Nature, 2003; 432: 235-40.
20. Yi R, Qin Y, Macara IG., Gullen, BR. Exportin-5 mediates the genesis of micro-RNAs. Nature 2003; 432: 235-40.
21. Preall JB, Sontheimer EJ. RNAi: RISC gets loaded. Cell 2005; 123: 543-45.
22. Lewis BP, Burge CB, Bartel DP. Conversed seed pairing, often flanked by adenosines, indicates that thousands of human genes are micro-RNA targets. Cell 2005; 120: 15-20.
23. Dickins RA, Hemann MT, Zilfou JT, et al. Probing tumor phenotypes using stable and regulated synthetic micro-RNA precursors. Nat Genet 2005, 37: 1289-95.
24. Bi F, Liu N, Fan D. Small interfering RNA: a new tool for gene therapy. Curr Gene Ther 2003; 3: 411-7.
25. Schwarz DS, Ding H, Kennington L, et al. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2006; 2: 1307-18.
26. Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 2001; 114: 4557-65.
27. Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 2003; 31: 589-95.
28. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue Factor. Nucleic Acids Res 2002; 30: 1757-66.
29. Ding H, Schwarz DS, Keene A, et al. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2003; 2: 209-17.
30. Ralph GS, Radcliffe PA, Day DK et al. Silencing mutant SOD1 using RNAi protects against neuro-degeneration and extends survival in an ALS model. Nat Med 2005; 11: 429-33.
31. Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuro-pathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005; 102: 5820-5.
32. Miller VM, Gouvion CM, Davidson BL, Paulson HL. Targeting Alzheimer's disease genes with RNA interference: An efficient strategy for silencing mutant alleles. Nucleic Acids Res 2004; 32: 661-8.
33. Lee SK, Dykxhoorn DM, Kumar P, et al. Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood 2005; 106: 818-26.
34. Li Z, Xiong Y, Peng Y, et al. Specific inhibition of HIV-1 replication by short hairpin RNAs targeting human cyclin T1 without inducing apoptosis. FEBS Lett 2005, 579: 3100-06.
35. Dykxhoorn DM, Schlehuber LD, London IM, Lieberman J. Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism. Proc Natl Acad Sci USA, 2006; 103: 5953-8.
36. Martinez LA, Naguibneva I, Lehrmann H, et al. Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 2002, 99: 14849-54.
37. Du Q, Thonberg H, Wang J, Wahlestedt C, Liang Z. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res 2005; 33: 1671-7.
38. Schwarz DS, Ding H, Kennington L, et al. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2006; 2: 1307-18.
39. Chiu YL, Rana TM. RNAi in human cells: Basic structural and functional features of small interfering RNA. Mol Cell 2002; 10: 549-61.
40. Haley B, Zamore PD. Kinetic analysis of the RNAi enzyme complex. Nat Struct Mol Biol 2004; 11: 599-606.
41. Korade-Mirnucs Z, Babitzke P, Hoffman E. Myotonic dystrophy: molecular windows on a complex etiology. Nucleic Acids Res 1998; 26: 1363-8.
42. Timchenko LT. Myotonic dystrophy: the role of RNA CUG triplet repeats. Am J Hum Genet 1999; 64: 360-4.
43. Wang X, Liledjian M, Weiss IM, Liebhaber SA. Detection and characterization of a 3′ untranslated region ribonucleoprotein complex associated with human alpha-globin mRNA stability. Mol Cell Biol 1995; 15: 1769-77.
44. Morales J, Russell JE, Liebhaber SA. Destabilization of human alpha globin mRNA by translation anti-termination is controlled during erythroid differentiation and is paralleled by phased shortening of the poly(A) tail. J Biol Chem 1997; 272: 6607-13.
45. Kobayashi K, Nakahori Y, Miyake M, et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998; 394: 388-92.
46. Hsieh AC, Bo R, Manola J, et al. A library of siRNA duplexes targeting the phosphiinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res 2004; 32: 893-910.
47. Mcanuff MA, Rettig GR, Rice KG. Potency of siRNA versus shRNA mediated knockdown in vivo. J Pharm Sci 2007; 96: 2922-30.
48. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005; 23: 222-6.
49. Siolas D, Lerner C, Burchard JL, et al. Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 2005; 23: 227-31.
50. Vlassov AV, Korba B, Farrar K, et al. shRNAs targeting hepatitis C: effects of sequence and structural features, and comparison with siRNA. Oligonucleotides 2007; 17: 223-36.
51. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNA for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001; 20: 6877-88.
52. Huang S-L, Wu Y, Yu H, et al. Inhibition of Bcl-2 expression by a novel tumor-specific RNA interference system increases chemosensitivity to 5-fluorouracil in Hela cells. Acta Pharmacol Sin 2006; 27: 242-8.
53. Gou D, Narasaraju T, Chintagari NR, Jin N, Wang P, Liu L. Gene silencing in alveolar type II cells using cell-specific promoter in vitro and in vivo. Nucleic Acids Res 2004; 32: e134.
54. Paddison OJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16: 948-58.
55. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-3.
56. Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilizing modification s of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003; 31: 2705-16.
57. Beal J. Silence is golden: can RNA interference therapeutics deliver? Drug Discov Today 2005; 10: 169-72.
58. Bitko V, Musiyenko A, Shulyayeva O, Aarik S. Inhibition of respiratory ratory virus by nasally administered siRNA. Nat Med 2005; 11: 50-5.
59. Zhang X, Shan P, Jiang D, et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion induced lung apoptosis. J Biol Chem 2004; 279: 10677-84.
60. Li W, Szpka FC. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res Adv Drug Deliv Rev 2007; 24: 438-49.
61. Foged C, Nielsen HM, Frokjaer S. Phospholipase A2 sensitive liposomes for delivery of small interfering RNA (siRNA). J Liposome Res 2007; 17: 191-6.
62. Torchilin V. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 2006; 8: 343-75.
63. Li W, Szpka FC. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res Adv Drug Deliv Rev 2007; 24: 438-49.
64. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-8.
65. Morris KV, Rossi JJ. Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther 2006; 13: 553-8.
66. Grimm D, Kay MA: Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther 2006; 13: 563-75.
67. Birmingham A, Anderson EM, Reynolds A, et al. 3′UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006; 3: 199-204.
68. Heidel J, Ju S, Liu X, Triche T, Davis M. Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 2004; 22: 1579-82.
69. Ma Z, Li J, He F, Wilson A, Pitt B, Li S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun 2005; 330: 755-9.
70. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34: 263-4.
71. Manche L, Green SR, Schmedt C, Mathews MB. Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol Cell Biol 1992; 12: 5238-48.
72. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 834-9.
73. Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res 2006; 16: 141-7.
74. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-a by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11: 263-70.
75. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23: 457-62.
76. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to over-saturation of cellular micro-RNA/short hairpin RNA pathways. Nature 2006; 441: 537-41.
77. Uprichard SL. The therapeutic potential of RNA interference. FEBS Lett 2005; 579: 5996-6007.
78. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 54: 825.
79. Wills-Karp M. Immunologic basis of antigen-induced airway hyper-responsiveness. Annu Rev Immunol 1999; 17: 255.
80. Toda M, Ono SJ. Genomics and proteomics of allergic disease. Immunology 2002; 106: 1-10.
81. Holgate ST, Davies DE, Rorke S, et al. Identification and possible functions of ADAM33 as an asthma susceptibility gene. Clin Exp All Rev 2004; 4: 49-55.
82. Finotto S, de Sanctis G.T, Lehr HA, et al. Treatment of allergic airway inflammation and hyper-responsiveness by anti-sense-induced local blockade of GATA-3 expression. J Exp Med 2001; 193: 1247-60.
83. Lee CC, Huang, HY, Chiang BL. Lentiviral mediated GATA-3 RNAi decreases allergic airway inflammation and hyper-responsiveness. Mol Ther 2007; 16: 60-65.
84. Platz J, Pinkenburg O, Beisswenger C, Puchner A, Damm T, Bals R. Application of small interfering RNA (siRNA) for modulation of airway epithelial gene expression. Oligonucleotides 2005; 15: 132-8.
85. Rippmann J, Schnapp A, Weith A, Hobbie, S. Gene silencing with STAT6 specific siRNAs blocks eotaxin release in IL-4/TNF-α stimulated human epithelial cells. FEBS Lett 2005; 579: 173-8.
86. Popescu FD. New asthma drugs acting on gene expression. J Cell Mol Med 2003; 7: 475-86.
87. Rivera J, Olivera A. Src family kinases and lipid mediators in control of allergic inflammation. Immunol Rev 2007; 217: 255-68.
88. Lee JH, Ko NY, Kim NW, et al. Meliae cortex extract exhibits anti-allergic activity through the inhibition of Syk kinase in mast cells. Toxicol Appl Pharmacol 2007; 220: 227-34.
89. Morel PA, Oriss TB. Cross-regulation between Th1 and Th2 cells. Crit Rev Immunol 1998; 18: 275-303.
90. Kopf M, Le Gros G, Bachmann M, Laemars MC, Bluethmann H, Köhler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362: 245-8.
91. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD41 T cells. Annu Rev Immunol 1994; 12: 635-73.
92. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282: 2261-3.
93. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258-61.
94. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin-5 deficiency abolishes airways eosinophilia and lung damage in mouse asthma model. J Exp Med 1996; 183: 195-201.
95. Kopf M, Brombacher F, Hodgkin PD, et al. IL-5 deficient mice have a development defect in CD5+B-1 cells and lack eosinophils but have normal antibody and cytotoxic; T cell responses. Immunity 1996, 4: 15-24.
96. Dent LA, Strath M, Mellor AL, Sanderson CJ. Eosinophdia in transgenic mice expressing interleukin 5. J Exp Med 1990; 172: 1425-31.
97. Coffman RL, Seymour BWP, Hudak S, Jackson J, Rennick, D. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science 1989; 245: 308-10.
98. Huang H, Lee CC, Chiang BL. Small interfering RNA against interleukin-5 decreases airway eosinophilia and hyper-responsiveness. Gene Ther 2008; 15: 660-7.
99. Kips JC, Tavernier JR, Joos GF, Peleman RA, Pauwels RA. The potential role of tumor necrosis factor a in asthma. Clin Exp Allergy 1993; 23: 247-50.
100. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component high-affinity blockers of cytokine action. Nat Med 2003; 9: 47-52.
101. Rossi D, Ziotnik, A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-42.
102. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002; 2: 106-15.
103. CLukacs NW, Berm A, Schols D, Skerij RT, Bridger GJ. AMD3100, a CxCR4 antagonist attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol 2002; 160: 1353-60.
104. nCCR2-/- mice: the role of mast cells. J Immunol 1999; 163: 265-74.
105. Erin EM, Willams TJ, Barnes PJ, Hansel TT. Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr Drug Targets Inflamm Allergy 2001; 1: 201-4.
106. Lioyd CM, Delaney T, Nguyen T, et al, CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J Exp Med 2000; 191: 265-74.
107. Bochner B. Adhesion molecules as therapeutic targets. Immunol Allergy Clin N Am 2004; 24: 615-30.
108. Gonzalo JA, Lloyd CM, Kremer L, et al. Eosinophil recruitment to the lung in a murine model of allergic inflammation-the role of T cells chemiokines, adhesion receptors. J Chn Invest 1996; 98: 2332-5.
109. Yang JT, Rayburn H, Hynes RO. Cell adhesion events mediated by a4 integrins are essential in placental and cardiac development. Development 1995; 121: 549-80.
110. Schleimer RP, Bochner BS. The rote of adhesion molecules in allergic inflammation and their suitability as targets of anti-allergic therapy. Clin Exp Allergy 1998; 28: 15-23
111. Bochner BS. Cellular adhesion and its antagonism. J Allergy Clin Immunol 1997; 100: 581-5.
112. Bochner BS. Cellular adhesion in inflammation. In: Adkinson NF Jr, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER Eds, Middleton's Allergy Principles and Practice, 6th Edition. St. Louis, Mosby Press 2003; pp. 117-34.
113. Bochner BS, Schleimer RP. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev 2001, 179: 5-15.
114. Yamamoto H, Nagata M. Regulatory mechanisms of eosinophil adhesion to and transmigration across endothelial cells by α4 and β2 intergrins. Int Arch Allergy Immunol 1999; 120: 24-6.
115. Wegner CD, Gundel RH, Reilly P, Haynes N, Letts LG, Rothlein R. Intra-cellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 1990 247: 456-9.
116. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Eng J Med 2003; 348: 24-32.
117. Abraham WM, Ahmed A, Sabater JR, et al. Selectin blockage prevents antigen-induced late bronchial responses and airway hyper-responsiveness in allergic sheep. Am J Respir Crit Care Med 1999; 159: 1205-14.
118. Kim MK, Brandley BK, Anderson M.B, Bochner BS. Antagonism of selectin-dependent adhesion of human eosinophils and neutrophils by glycomimetics and oligosaccharide compounds. Am J Respir Cell Mol Biol 1998; 19: 8364-41.
119. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering (siRNA) targeting VEGF effectively inhibits ocular neo-vascularization in a mouse model, Mol Vis 2003; 9: 210-6
120. Shirakawa T, Deichmann KA, Izuhara I, Mao I, Adra CN, Hopkin JM. Atopy and asthma genetic variants of IL-4 and IL-13 signaling. Immunol Today 2000; 21: 60-4.
121. Suzuki I, Hizawa N, Yamaguchi E, Kawakami Y. Association between a C+33T polymorphism in the IL-4 promoter region and total serum IgE levels. Clin Exp Allergy 2000; 30: 1746-9.
122. Liu X, Nickel R, Beyer K, et al. An IL13 coding region variant is associated with a high total serum IgE level and atopic dermatitis in the German multi-center atopy study (MAS-90). J Allergy Clin Immunol 2000; 106: 167-70.
123. Graves PE, Kabesch M, Halonen M, et al. A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J Allergy Clin Immunol 2000: 106: 167-70.
124. Heinzmann A, Mao XQ, Akiwa M, et al. Genetic variants of IL-13 signaling and human asthma and atopy. Hum Mol Genet 2000; 9: 549-59.
125. Andrews RP, Burrell L, Rosa-Rosa L, et al. Analysis of the Ser786Pro interleukin-4 receptor alpha allelic variant in allergic and non-allergic asthma and its functional consequences. Clin Immunol 2001; 100: 298-304.
126. Kruse S, Japan T, Tednet M et al. The polymorphisms S503P and Q576R in the interleukin-4 receptor alpha gene are associated with atopy and influence the signal transduction. Immunology 1999; 96: 365-71.
127. Grimbacher B, Holland SM, Puck JM. The interleukin -4 receptor variant Q576R in hyper-IgE syndrome. N Engl J Med 1998; 338: 1073-4.
128. Oiso N, Fukat K, Ishii M. Interleukin 4 receptor alpha chain polymorphism in Japan. Br J Dermatol 2000; 141: 1003-6.
129. Hershey GK, Friedrich NO, Esswein LA, Thomas ML, Chatila T.A. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 1997; 337: 1720-5.
130. Lara-Marquez ML, Yunis JJ, Layrisse 4, et al. Immunogenetics of atopic asthma: association of DRB1 * 1101DQA1*0501 DQB1* 0301 haplotype with Dermatophagoides. spp.-sensitive asthma in a sample of the Venezuelan population, Clin Exp Allergy, 1999; 29: 60-71.
131. D'Amato M, Scotto d'Abusco A, Maggi E, et al. Association of responsiveness to the major pollen allergen of Parietaria officinalis with HLA-DRB1* alleles: a multi-center study. Hum Immunol 1996; 46: 100-6.
132. Donfack J, Tsalenko A, Hoki DM, et al. HLA-DRB1*01 alleles are associated with sensitization to cockroach allergens. J Allergy Clin Immunol 2000; 105: 960-6.
133. Fryer AA, Spiteri MA, Bianco A, et al. The -403 G-A promoter polymorphism in the RANTES gene is associated with atopy and asthma. Genes Immunol 2000; 1: 509-14.
134. Nickel RG, Casolaro V, Wahn U, et al. Atopic dermatitis is associated with a functional mutation in the promoter of the CC chemokine RANTES, J Immunol 2000; 164: 1212-6.
135. Tsunemi Y, Saeki H, Nakamura K, et al. Eotaxin gene single nucleotide polymorphisms in the promoter and exon regions are not associated with susceptibility to atpoic dermatitis, but two of them in the promoter region are associated with serim. IgE levels in patients with atopic dermatitis. J Dermatol Sci 2002; 29: 222-8.
136. Fukunaga K, Asano Y, Mao XQ, et al. Genetic polymorphism of CC chemokine receptor 3 in Japanese and British asthmatics. Eur Respir J 2001; 17: 59-63.